Hi-Tech Pharmacal Company Profile (NASDAQ:HITK)

About Hi-Tech Pharmacal (NASDAQ:HITK)

Hi-Tech Pharmacal logoHi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:HITK
  • CUSIP: 42840B10
  • Web: N/A
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 15.76
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Hi-Tech Pharmacal (NASDAQ:HITK)

What is Hi-Tech Pharmacal's stock symbol?

Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."

Who are some of Hi-Tech Pharmacal's key competitors?

How do I buy Hi-Tech Pharmacal stock?

Shares of Hi-Tech Pharmacal can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Hi-Tech Pharmacal stock cost?

One share of Hi-Tech Pharmacal stock can currently be purchased for approximately $43.49.

Analyst Ratings

Consensus Ratings for Hi-Tech Pharmacal (NASDAQ:HITK) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hi-Tech Pharmacal (NASDAQ:HITK)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Hi-Tech Pharmacal (NASDAQ:HITK)
Earnings by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
Earnings History by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/11/2014Q314$0.66$0.70$62.35 million$59.90 millionViewN/AView Earnings Details
12/10/2013Q2$0.47$0.71$57.97 million$58.60 millionViewN/AView Earnings Details
9/9/2013Q1 2014$0.44$0.44$57.78 million$50.50 millionViewListenView Earnings Details
7/9/2013Q4 2013$0.63$0.50$66.33 million$58.50 millionViewListenView Earnings Details
3/7/2013Q3 2013$0.71$0.43$60.45 million$64.33 millionViewListenView Earnings Details
12/6/20120.66$0.66$57.54 millionViewListenView Earnings Details
9/5/2012Q113$0.68$0.44$57.60 million$52.00 millionViewN/AView Earnings Details
7/10/2012$0.78$0.73ViewN/AView Earnings Details
3/8/2012$0.87$0.79ViewN/AView Earnings Details
12/5/2011$0.77$1.04ViewN/AView Earnings Details
9/7/2011$0.84$1.05ViewN/AView Earnings Details
7/7/2011$0.71$0.98ViewN/AView Earnings Details
3/10/2011$0.63$0.79ViewN/AView Earnings Details
12/9/2010$0.56$0.76$42.47 million$44.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hi-Tech Pharmacal (NASDAQ:HITK)
Current Year EPS Consensus Estimate: $2.38 EPS
Next Year EPS Consensus Estimate: $2.76 EPS

Dividends

Dividend History for Hi-Tech Pharmacal (NASDAQ:HITK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hi-Tech Pharmacal (NASDAQ:HITK)
Insider Trades by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
Insider Trades by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/13/2013Gary AprilInsiderSell6,873$43.06$295,951.38View SEC Filing  
10/10/2013Reuben SeltzerChairmanSell11,250$43.13$485,212.50View SEC Filing  
10/8/2013David SeltzerCEOSell23,000$43.09$991,070.00View SEC Filing  
10/4/2013Martin GoldwynDirectorSell1,500$43.10$64,650.00View SEC Filing  
10/3/2013William J PetersCFOSell21,250$43.11$916,087.50View SEC Filing  
10/2/2013Bruce W SimpsonDirectorSell25,468$43.15$1,098,944.20View SEC Filing  
10/2/2013Reuben SeltzerChairmanSell11,250$43.13$485,212.50View SEC Filing  
2/5/2013William J PetersCFOSell4,639$38.00$176,282.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hi-Tech Pharmacal (NASDAQ:HITK)
Latest Headlines for Hi-Tech Pharmacal (NASDAQ:HITK)
Source:

Social

Chart

Hi-Tech Pharmacal (HITK) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff